Reference Member State (RMS) in EU Regulatory Affairs

Purpose and Scope

The Reference Member State (RMS) is the Member State whose competent authority leads the scientific assessment and procedural coordination of a medicinal product in the EU mutual-recognition procedure (MRP) or decentralised procedure (DCP). Other participating countries are Concerned Member States (CMSs).

The RMS is not a supranational regulator and does not replace the competent authorities of the CMSs. It is a national authority performing a legally defined coordinating role within a European procedure. The CMSs review the RMS assessment, raise issues and ultimately issue or maintain their own national marketing authorisations in accordance with the outcome of the coordinated procedure.

Understanding that distinction prevents a common conceptual error: treating the RMS as though it were the equivalent of EMA or CHMP. EMA coordinates the centralised EU system and several Union procedures; an RMS acts within the MRP/DCP framework for nationally authorised products.

Legal Basis

Article 28 of Directive 2001/83/EC provides the core legal framework. An applicant seeking authorisation for a medicinal product in more than one Member State submits an application based on an identical dossier and requests one Member State to act as the reference Member State and prepare the assessment report.

Article 28 then distinguishes two situations:

• where the medicinal product already has a national marketing authorisation, the other Member States are asked to recognise that authorisation through the mutual-recognition procedure;
• where the medicinal product does not yet have a marketing authorisation, the RMS prepares a draft assessment report and draft product information for coordinated assessment in the decentralised procedure.

The legal role of the RMS therefore follows directly from EU pharmaceutical legislation; it is not merely an administrative convention created by the coordination group.

Where the RMS Fits in the EU Authorisation System

The EU has several routes by which a medicine can be authorised. The RMS concept belongs specifically to the MRP/DCP framework.

A product can later enter other Union procedures, including referrals, PSUR single assessments or signal-related processes, but that does not transform the RMS into an EU institution.

RMS in the Decentralised Procedure

The DCP is used when a product is not yet authorised in the EU and the applicant seeks simultaneous authorisation in several Member States. One Member State agrees to act as RMS. The others participate as CMSs.

Under Article 28(3), the RMS prepares the draft assessment report, draft summary of product characteristics, labelling and package leaflet and circulates them to the CMSs and applicant. The CMSs review the assessment and raise comments or objections through the coordinated procedure.

The practical sequence is:

identical dossier submitted → RMS leads assessment → CMSs review and comment → issues resolved through the procedure → common position reached → national competent authorities grant national authorisations

The CMDh publishes current procedural guidance, standard operating procedures, assessment templates and annual recommendations for DCP submission and RMS requests. These materials support consistent implementation of the legal framework but do not replace Article 28 itself.

RMS in the Mutual-Recognition Procedure

MRP begins from an existing national marketing authorisation. Under Article 28(2), the marketing-authorisation holder requests the RMS to prepare or, where necessary, update the assessment report. That assessment and the approved product information are then provided to the CMSs for recognition.

Conceptually, the difference from DCP is the starting point:

• DCP: no existing national marketing authorisation; assessment is coordinated before the first authorisations are granted.
• MRP: an existing RMS authorisation provides the basis for recognition in additional Member States.

This distinction affects the dossier history, procedural documentation and the regulatory questions likely to arise, although both routes rely on an RMS/CMS coordination model.

The Assessment Report

The assessment report is central to the RMS role. It sets out the scientific and regulatory reasoning supporting the evaluation of quality, safety, efficacy and benefit-risk as relevant to the application. It also supports the proposed product information.

The report is not simply the RMS's private view. It becomes the common scientific reference for the coordinated procedure and is scrutinised by the CMSs. Good RMS work therefore depends on transparent reasoning, clear identification of unresolved issues and a record that allows other competent authorities to understand why a conclusion was reached.

CMDh maintains best-practice guidance and templates for MRP/DCP assessment reports. These procedural tools help harmonise the format and exchange of regulatory reasoning across Member States.

Relationship Between RMS and Concerned Member States

The RMS leads; the CMSs participate. That relationship is collaborative rather than hierarchical. CMSs review the assessment, test whether the proposed benefit-risk conclusion and product information are acceptable, and raise issues that need resolution. The RMS coordinates responses and maintains the common assessment record, but it cannot simply disregard a substantiated concern from another Member State.

The quality of the procedure therefore depends on two complementary functions: a sufficiently rigorous lead assessment by the RMS and sufficiently critical review by the CMSs. An efficient procedure is not one in which CMSs raise no questions; it is one in which questions are proportionate, scientifically clear and resolved in a traceable way.

Potential serious risk to public health

Where a CMS cannot accept the assessment because it considers that the product may present a potential serious risk to public health, the disagreement is not treated as an ordinary drafting preference. The Directive provides a formal mechanism for unresolved disagreement and coordination through CMDh.

The concept is important because not every scientific difference should escalate into a referral. The regulatory threshold is linked to a potential serious risk to public health, and current CMDh/European Commission guidance should be consulted when assessing whether that threshold is met.

CMDh and Unresolved Disagreement

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) is established under Article 27 of Directive 2001/83/EC and addresses questions relating to MRP/DCP and certain pharmacovigilance procedures.

If agreement cannot be reached during the MRP/DCP because of a potential serious risk to public health, the matter can proceed to CMDh under the applicable provisions of Article 29. CMDh provides a structured forum for Member States to seek agreement. Depending on the outcome and the legal pathway, further Union-level referral mechanisms may apply.

For the applicant or MAH, the practical lesson is that RMS coordination does not eliminate the need to understand CMS concerns. A response should address the scientific substance of the objection and explain how the proposed product information or benefit-risk conclusion manages it.

RMS Responsibilities After Initial Authorisation

The RMS role does not end when the first MRP/DCP closes. The product remains part of a coordinated regulatory history that may include variations, renewals, repeat-use procedures, product-information harmonisation and risk-management activities.

Current CMDh/HMA procedural guidance provides detailed arrangements for many post-authorisation activities. The exact role of the RMS varies by procedure, but it commonly continues to coordinate assessment or provide the scientific reference point for changes affecting the mutually recognised/decentralised product family.

Variations

For many variations affecting MRP/DCP products, the RMS coordinates assessment and communication with CMSs under the applicable variations framework and CMDh best-practice guidance. The detailed timelines and procedural rules depend on variation type and the current legal framework. These should be checked from current HMA/CMDh guidance rather than relying on historical procedure descriptions.

Renewals and repeat-use procedures

Where applicable, the RMS supports coordinated renewal activities and repeat-use procedures. In repeat use, an existing MRP/DCP authorisation may be extended to additional Member States. The procedural history should remain traceable so that the current product information and assessment basis are clear across all participating countries.

RMS and Pharmacovigilance

The RMS is principally an authorisation-procedure role, but it has continuing pharmacovigilance significance for nationally authorised products. Safety changes often need coordinated implementation across an MRP/DCP product family, and the RMS can have an important assessment and coordination role depending on the procedure.

This is particularly visible in risk-management plans for products authorised through MRP/DCP. EMA's report on pharmacovigilance tasks in Member States for 2019–2022 described RMPs for MRP/DCP products as being submitted to the competent authorities of the Member States where the product is authorised, with assessment undertaken by a single Member State acting as RMS and recognised by the CMSs. The precise procedural arrangements should be checked against current guidance for the product and submission type.

Safety variations and product information

New safety information may require changes to the SmPC, package leaflet or labelling. Where the product is authorised in several Member States through MRP/DCP, coordinated implementation is essential so that national product information does not diverge without justification.

The RMS may coordinate the relevant variation assessment, while CMSs retain their national authority responsibilities. The MAH must therefore manage both the common procedure and country-level implementation.

RMP interfaces

An RMP can create additional coordination complexity because risk-minimisation measures may require national adaptation. The RMS assessment can provide the common scientific basis, but national competent authorities may still have local implementation requirements for additional risk-minimisation materials.

A pharmacovigilance professional should therefore distinguish three layers:

1. the common safety strategy and RMP assessment;
2. the coordinated RMS/CMS regulatory procedure;
3. national implementation of approved measures.

Confusing these layers can lead to assumptions that an RMS approval automatically determines every local operational detail.

Relationship with the QPPV and MAH

The RMS is a regulatory authority role; the QPPV is an MAH pharmacovigilance role. They are not counterparts in a formal one-to-one governance structure.

The MAH must ensure that regulatory commitments and safety changes arising from the MRP/DCP system are integrated into its pharmacovigilance system. The QPPV should have sufficient oversight of safety-relevant regulatory actions, but the exact internal workflow between regulatory affairs and pharmacovigilance is an organisational matter.

Good practice is to ensure that safety-related RMS/CMS correspondence, RMP assessments, variation outcomes and implementation commitments are visible to the functions responsible for benefit-risk evaluation, signal management, aggregate reporting and risk minimisation.

Practical Regulatory Management

A strong MAH process maintains a clear procedure map for each MRP/DCP product, including the RMS, CMSs, procedure number, national authorisations, current product information, variation history and applicable RMP status.

This is more than regulatory housekeeping. A safety signal can require rapid identification of which Member States are affected, whether product information is harmonised, which procedure will implement the change and what local risk-minimisation actions are needed.

The RMS/CMS structure therefore becomes part of the product's pharmacovigilance operating context even though the underlying role originates in marketing-authorisation legislation.

Special Situations

Change of RMS

An RMS can change in certain circumstances, but this is not an informal MAH choice made simply for convenience after a procedure has begun. The applicable CMDh/HMA procedural guidance and agreement of the competent authorities should be followed. Where a change occurs, transfer of the regulatory history, assessment record and ongoing commitments needs to be controlled so that the new RMS can fulfil the coordinating role without loss of context.

Repeat-use procedures

A product already authorised through MRP/DCP may be introduced into additional Member States through repeat use. The RMS remains the scientific reference point for the procedure, while newly participating countries become CMSs for that wave. The MAH should ensure that the dossier, assessment history and product information used for repeat use reflect the current authorised state rather than the original historical submission.

Products with divergent national histories

Legacy products may have national authorisation histories that pre-date harmonised MRP/DCP arrangements. Where product information or indications differ, the existence of an RMS for a later procedure does not automatically erase historical national differences. The correct regulatory route for harmonisation must be determined from the product's legal and procedural status.

Safety issues that move beyond the RMS/CMS framework

Some safety matters are handled through Union-level pharmacovigilance procedures rather than remaining solely within the ordinary MRP/DCP variation framework. Examples can include referrals, PSUR single assessment or EU signal-management outcomes. In such cases the RMS remains relevant to the product's national authorisation history, but the legal procedure governing the safety action determines who assesses and how the outcome becomes binding.

This distinction prevents overstatement of the RMS role. The RMS is important, but it is not the lead authority for every safety process affecting a nationally authorised medicine.

Potential Failure Modes

Illustrative regulatory-management failures include:

• treating the RMS as though it were the sole competent authority for all participating countries;
• confusing DCP with MRP and therefore misunderstanding the starting regulatory status of the product;
• assuming that an RMS scientific assessment automatically resolves every national implementation requirement;
• failing to maintain a reliable record of current RMS, CMSs, procedure numbers and national authorisations;
• allowing safety-related product information to diverge across Member States because implementation was tracked only centrally;
• escalating ordinary scientific disagreement as a potential serious risk to public health without considering the applicable threshold;
• assuming that every post-authorisation pharmacovigilance procedure is led by the RMS;
• relying on historical CMDh timelines or templates without checking the current procedural guidance.

These are illustrative operational risks, not asserted inspection findings.

Inspection and Governance Considerations

From a pharmacovigilance-system perspective, an inspector may be less interested in the abstract definition of an RMS than in whether the MAH can translate coordinated regulatory decisions into controlled safety action across countries.

Illustrative questions include:

• Can the organisation identify the current RMS and all CMSs for the product?
• Is the current national product information consistent with the coordinated outcome?
• How are RMS/CMS safety variations communicated to pharmacovigilance functions?
• How are RMP commitments and additional risk-minimisation measures tracked across Member States?
• If a Union procedure superseded the ordinary RMS/CMS pathway, was the change in governance recognised?
• Can the MAH reconstruct the regulatory rationale and implementation status from source records?

The evidence chain should connect the common European procedure to each national authorisation and to the pharmacovigilance system that monitors the product after authorisation.

Practical Checklist

For an MRP/DCP product, maintain at least a controlled understanding of:

• the RMS and participating CMSs;
• whether the original route was MRP, DCP or repeat use;
• the procedure number and regulatory history;
• the current assessment report and product information status;
• open variations, renewals or other coordinated procedures;
• current RMP status where applicable;
• national implementation of safety-related changes;
• interfaces with Union-level pharmacovigilance procedures.

Key Takeaways

The Reference Member State is the national competent authority that leads assessment and coordination in the mutual-recognition and decentralised procedures. Its role is legally grounded in Article 28 of Directive 2001/83/EC and implemented through current CMDh/HMA procedural guidance.

The RMS does not replace the CMSs, EMA, CHMP or other Union pharmacovigilance mechanisms. Its importance lies in providing a common scientific reference and coordinating a procedure that ultimately results in national marketing authorisations. For pharmacovigilance professionals, the RMS/CMS structure matters because safety changes, RMP activities and product-information updates must be translated consistently across the nationally authorised product family.

References

1. European Union. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Articles 27–29, including Article 28 on mutual-recognition and decentralised procedures.
2. Heads of Medicines Agencies, CMDh. Best Practice Guide for the Decentralised and Mutual Recognition Procedures. Current procedural guidance available through the HMA/CMDh website.
3. Heads of Medicines Agencies, CMDh. Decentralised Procedure Members States' Standard Operating Procedure and current DCP procedural materials.
4. Heads of Medicines Agencies, CMDh. Best Practice Guide on the Assessment Report for Mutual Recognition and Decentralised Procedures. Current version available through HMA.
5. Heads of Medicines Agencies, CMDh. Variation procedural guidance and Best Practice Guides. Current versions, including 2025–2026 updates where applicable.
6. European Medicines Agency. Concerned Member State and related EU regulatory glossary material.
7. European Medicines Agency. Report on pharmacovigilance tasks from EU Member States and EMA, 2019–2022, including description of RMS assessment of RMPs for MRP/DCP products.

Regulatory Note

MRP/DCP procedures, timelines, templates and post-authorisation processes are governed by EU legislation and detailed CMDh/HMA procedural guidance that is periodically revised. The Directive establishes the legal role of the RMS, while current procedural documents should be consulted for operational requirements. Product-specific national and Union procedures may alter which authority or committee leads a particular post-authorisation safety action.